MEK inhibitors have shown promise in combating tumorigenesis as both monotherapy and combined therapy in several malignancies, including V600E melanoma, non-small cell lung cancer, breast cancer, and colorectal cancer [1]. Here, MAP2K7 is linked to breast carcinoma.